Entry Name Renal cell carcinoma - Homo sapiens (human)
Description Renal cell cancer (RCC) accounts for ~3% of human malignancies and its incidence appears to be rising. Although most cases of RCC seem to occur sporadically, an inherited predisposition to renal cancer accounts for 1-4% of cases. RCC is not a single disease, it has several morphological subtypes. Conventional RCC (clear cell RCC) accounts for ~80% of cases, followed by papillary RCC (10-15%), chromophobe RCC (5%), and collecting duct RCC (<1%). Genes potentially involved in sporadic neoplasms of each particular type are VHL, MET, BHD, and FH respectively. In the absence of VHL, hypoxia-inducible factor alpha (HIF-alpha) accumulates, leading to production of several growth factors, including vascular endothelial growth factor and platelet-derived growth factor. Activated MET mediates a number of biological effects including motility, invasion of extracellular matrix, cellular transformation, prevention of apoptosis and metastasis formation. Loss of functional FH leads to accumulation of fumarate in the cell, triggering inhibition of HPH and preventing targeted pVHL-mediated degradation of HIF-alpha. BHD mutations cause the Birt-Hogg-Dube syndrome and its associated chromophobe, hybrid oncocytic, and conventional (clear cell) RCC.
Class Human Diseases; Cancer: specific typesBRITE hierarchy
Pathway map Ortholog table Network Element N00005 Mutation-activated MET to RAS-ERK signaling pathway
N00044 Mutation-activated MET to PI3K signaling pathway
N00080 Loss of VHL to HIF-1 signaling pathway
N00081 Mutation-inactivated VHL to HIF-1 signaling pathway
N01873 VHL mutation to HIF-2 signaling pathway
Disease Drug D06272 Sorafenib tosylate (USAN)
D10095 Cabozantinib s-malate (USAN)
D11954 Belzutifan (JAN/USAN/INN)
Organism Homo sapiens (human) [GN:
hsa ]
Gene 3091 HIF1A; hypoxia inducible factor 1 subunit alpha [KO:K08268 ]
2034 EPAS1; endothelial PAS domain protein 1 [KO:K09095 ]
7428 VHL; von Hippel-Lindau tumor suppressor [KO:K03871 ]
405 ARNT; aryl hydrocarbon receptor nuclear translocator [KO:K09097 ]
9915 ARNT2; aryl hydrocarbon receptor nuclear translocator 2 [KO:K15589 ]
6513 SLC2A1; solute carrier family 2 member 1 [KO:K07299 ]
7422 VEGFA; vascular endothelial growth factor A [KO:K05448 ]
7040 TGFB1; transforming growth factor beta 1 [KO:K13375 ]
7042 TGFB2; transforming growth factor beta 2 [KO:K13376 ]
7043 TGFB3; transforming growth factor beta 3 [KO:K13377 ]
5155 PDGFB; platelet derived growth factor subunit B [KO:K17386 ]
7039 TGFA; transforming growth factor alpha [KO:K08774 ]
2549 GAB1; GRB2 associated binding protein 1 [KO:K09593 ]
5290 PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922 ] [EC:2.7.1.153 ]
5293 PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922 ] [EC:2.7.1.153 ]
5291 PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922 ] [EC:2.7.1.153 ]
5295 PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649 ]
5296 PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649 ]
8503 PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649 ]
572 BAD; BCL2 associated agonist of cell death [KO:K02158 ]
1398 CRK; CRK proto-oncogene, adaptor protein [KO:K04438 ]
1399 CRKL; CRK like proto-oncogene, adaptor protein [KO:K04438 ]
2889 RAPGEF1; Rap guanine nucleotide exchange factor 1 [KO:K06277 ]
5906 RAP1A; RAP1A, member of RAS oncogene family [KO:K04353 ]
5908 RAP1B; RAP1B, member of RAS oncogene family [KO:K07836 ]
2885 GRB2; growth factor receptor bound protein 2 [KO:K04364 ]
6654 SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099 ]
6655 SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099 ]
3265 HRAS; HRas proto-oncogene, GTPase [KO:K02833 ]
3845 KRAS; KRAS proto-oncogene, GTPase [KO:K07827 ]
4893 NRAS; NRAS proto-oncogene, GTPase [KO:K07828 ]
2113 ETS1; ETS proto-oncogene 1, transcription factor [KO:K02678 ]
3725 JUN; Jun proto-oncogene, AP-1 transcription factor subunit [KO:K04448 ]
998 CDC42; cell division cycle 42 [KO:K04393 ]
5546 PRCC; proline rich mitotic checkpoint control factor [KO:K13105 ]
7030 TFE3; transcription factor binding to IGHM enhancer 3 [KO:K09105 ]
1026 CDKN1A; cyclin dependent kinase inhibitor 1A [KO:K06625 ]
Compound Reference Authors Cohen HT, McGovern FJ.
Title Renal-cell carcinoma.
Journal Reference Authors Pavlovich CP, Schmidt LS.
Title Searching for the hereditary causes of renal-cell carcinoma.
Journal Reference Authors Linehan WM, Walther MM, Zbar B.
Title The genetic basis of cancer of the kidney.
Journal Reference Authors Kim WY, Kaelin WG.
Title Role of VHL gene mutation in human cancer.
Journal Reference Authors Sudarshan S, Linehan WM, Neckers L.
Title HIF and fumarate hydratase in renal cancer.
Journal Reference Authors Sudarshan S, Pinto PA, Neckers L, Linehan WM.
Title Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.
Journal Reference Authors Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.
Title Met, metastasis, motility and more.
Journal Reference Authors Muller-Hocker J, Babaryka G, Schmid I, Jung A
Title Overexpression of cyclin D1, D3, and p21 in an infantile renal carcinoma with Xp11.2 TFE3-gene fusion.
Journal Reference Authors Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG.
Title Understanding familial and non-familial renal cell cancer.
Journal Reference Authors Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM
Title Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.
Journal Reference Authors Skalsky YM, Ajuh PM, Parker C, Lamond AI, Goodwin G, Cooper CS
Title PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
Journal Reference Authors Medendorp K, van Groningen JJ, Vreede L, Hetterschijt L, Brugmans L, van den Hurk WH, van Kessel AG
Title The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21 WAF1/CIP1-mediated cell cycle delay.
Journal Related KO pathway LinkDB All DBs